Which medication should not be added for a patient with well-controlled asthma experiencing occasional symptoms?

For a patient with well-controlled asthma who experiences only occasional symptoms, adding a long-acting beta-agonist (LABA) is not recommended. LABAs are typically indicated for patients who require additional control beyond that provided by a low-dose inhaled corticosteroid or for those with more persistent symptoms.

In well-controlled asthma where symptoms are infrequent, short-acting beta-agonists (SABAs) are usually sufficient to manage occasional symptoms as they provide quick relief. Inhaled corticosteroids are often the foundation of maintenance therapy and are appropriate for long-term control. Leukotriene modifiers can be beneficial as adjunctive therapy but are also used for patients who may benefit from additional control without stepping up to a LABA.

Thus, introducing a LABA in a patient with well-controlled asthma experiencing only occasional symptoms does not align with current treatment guidelines and practice, making it an unsuitable choice in this context.